Tickers

1. Composite Trajectory Verdict

All three financial statements carry roughly equal weight for IFF because it is a capital-intensive specialty ingredients company where profitability, cash generation for debt service, and leverage management are all critical to assessing financial health.

Composite Trajectory: Mixed

The annual GAAP earnings trajectory is mixed, with net income swinging from a -$2.587B loss in 2023 to a +$263M profit in 2024 and back to a -$361M loss in 2025, driven by large goodwill impairments in 2023 and 2025 (10-K 2025-12-31, Consolidated Statements of Operations). Cash generation is deteriorating, as operating cash flow declined for three consecutive years: $1.455B (2023), $1.070B (2024), $0.850B (2025) (10-K 2025-12-31, Consolidated Statements of Cash Flows). The balance sheet is improving, with total debt falling from $8.977B (short-term $1.413B + long-term $7.564B) at end-2024 to $5.994B (short-term $1.254B + long-term $4.740B) at end-2025, cash rising to $590M from $469M, and shareholders’ equity increasing to $14.154B from $13.834B (10-K 2025-12-31, Consolidated Balance Sheets).

2. Red Flags

• Recurring goodwill impairments labeled non-recurring: $2.623B (2023), $64M (2024), $1.153B (2025) (10-K 2025-12-31, Consolidated Statements of Operations).
• Three-year decline in GAAP operating cash flow: $1.455B → $1.070B → $0.850M (10-K 2025-12-31, Consolidated Statements of Cash Flows).
• Wide and volatile gap between GAAP operating profit and non-GAAP Adjusted Operating EBITDA: GAAP operating profit -$382M vs. Adjusted EBITDA $2,086M in 2025; $766M vs. $2,205M in 2024 (10-K 2025-12-31, MD&A Segment Adjusted Operating EBITDA Results).
• Near-term debt maturity concentration: $940M of senior notes principal payable within 12 months as of Dec 31, 2025 (10-K 2025-12-31, Liquidity and Capital Resources).
• Working capital build cited as a driver of operating cash flow decline: “increase in working capital” noted in 2025 cash flow discussion (10-K 2025-12-31, Liquidity and Capital Resources).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: GAAP net income attributable to IFF shareholders swung from -$2.587B in 2023 to +$263M in 2024 to -$361M in 2025 (10-K 2025-12-31, Consolidated Statements of Operations). The volatility is dominated by goodwill impairment charges of $2.623B (2023), $64M (2024), and $1.153B (2025) (10-K 2025-12-31, Consolidated Statements of Operations). Excluding impairments, operating profit would have been $771M in 2025 (operating loss -$382M + impairment $1,153M) versus $830M in 2024 (operating profit $766M + impairment $64M), a modest decline. Reported net sales fell 5% to $10.890B in 2025 from $11.484B in 2024, while comparable currency-neutral sales rose 2% (10-K 2025-12-31, MD&A Overview). Gross margin expanded 30 bps to 36.2% in 2025 (10-K 2025-12-31, Consolidated Statements of Operations).

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Deteriorating

Overall Assessment: Net cash provided by operating activities declined for three straight years: $1.455B (2023), $1.070B (2024), $0.850B (2025) (10-K 2025-12-31, Consolidated Statements of Cash Flows). The 2025 decrease was attributed to “an increase in working capital and a larger incentive compensation payout” (10-K 2025-12-31, Liquidity and Capital Resources). Investing cash flow turned strongly positive in 2025 at $2.269B due to divestiture proceeds (Pharma Solutions, Nitrocellulose, Tobacco Flavoring, Rene Laurent) versus $326M in 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). Financing cash outflows increased to $3.091B in 2025 from $1.606B in 2024, driven by $2.0B of senior note repurchases and repayment of term loans (10-K 2025-12-31, Liquidity and Capital Resources). Capital expenditures rose to $594M in 2025 from $463M in 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Overall Assessment: Total debt (short-term + long-term) decreased from $8.977B at Dec 31, 2024 to $5.994B at Dec 31, 2025 (10-K 2025-12-31, Consolidated Balance Sheets). Cash and restricted cash increased to $590M from $469M (10-K 2025-12-31, Consolidated Balance Sheets). Shareholders’ equity rose to $14.154B from $13.834B (10-K 2025-12-31, Consolidated Balance Sheets). Goodwill fell to $8.269B from $9.075B, reflecting the $1.153B Food Ingredients impairment (10-K 2025-12-31, Consolidated Balance Sheets). The net debt to credit adjusted EBITDA ratio was 2.59x at Dec 31, 2025, below the 3.75x covenant threshold (10-K 2025-12-31, Liquidity and Capital Resources). Assets held for sale dropped from $3.056B to $151M as divestitures closed (10-K 2025-12-31, Consolidated Balance Sheets).

6. Data Gaps

• Quarterly GAAP income statement, cash flow, and balance sheet figures for comparable prior-year quarters (Q2 2024, Q3 2024, Q1 2025) are not present in the provided excerpts.
• Full 2023 balance sheet (total assets, debt, equity) is not included in the XBRL data provided.
• Free cash flow (operating cash flow minus capex) is not explicitly reported in the filings.
• Segment-level GAAP operating profit (vs. non-GAAP Adjusted EBITDA) is not disclosed in the provided tables.
• Complete 2023 cash flow statement (investing and financing details) is truncated in the provided XBRL.